New Stock News | Ze Hui Biology Port's IPO prospectus for public offering is invalidated, dedicated to developing innovative cell therapy products for PSC.

ZeHui Biotechnology Co., Ltd. (ZeHui Biotech) submitted its Hong Kong IPO prospectus on September 30, 2024, which expired on March 30, 2025, six months after submission, with CICC as its exclusive sponsor at the time of submission. The prospectus disclosed that ZeHui Biotech is a biopharmaceutical company in the clinical research and development stage, dedicated to developing innovative cell therapy products derived from pluripotent stem cells ("PSC") to treat a variety of diseases. As one of the earliest companies in China and even globally to engage in the research and development of PSC-derived cell therapy products, according to Frost & Sullivan data, the company is one of the first in China to obtain approval for PSC-derived cell therapy new drug clinical trial applications ("IND") and the only company in China currently with multiple PSC-derived cell therapy assets in Phase II clinical trials. Currently, the company's product portfolio includes the core product ZH901, as well as main products ZH903, ZH902, and ZH906. As of the last feasible date, the core product ZH901 has entered Phase II clinical trials for the treatment of AE-ILD, aGVHD, meniscus injury, and ARDS. ZH903 and ZH902 are main products currently being studied in investigator-initiated trials ("IIT"), aiming to treat Parkinson's disease and dry AMD, respectively. The company's main product ZH906, used for treating corneal endothelial decompensation, is in the preclinical stage.